TROP2 Drug Wins Two New Indications in Triple-Negative Breast Cancer

Trodelvy earns FDA approval as first-line treatment for triple-negative breast cancer

The FDA has approved sacituzumab govitecan-hziy as first-line therapy for adults with unresectable locally advanced or metastatic triple-negative breast cancer across PD-L1 status. Sacituzumab govitecan-hziy…